HAVCR2 and acute myeloid leukemia: Although a phase 1 study evaluating the blockade of TIM-3 (TSR-022) in advanced solid tumors is in progress (NCT02817633), further studies will be needed to determine the precise role of TIM-3 in AML after allo-HSCT.